Clinical trial · Interventional
Web-based Symptom Monitoring and Survival in Advanced Stage Lung Cancer
NCT05621902CI-TRIAL-00062263LUCA-Snot yet recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this clinical trial is to investigate if weekly symptom monitoring of patients with advanced lung cancer is associated with better survival and improved quality of life compared to standard follow-up. Each week, participants in the intervention group will be asked to respond to an electronic weekly questionnaire covering 11 items related to current health status.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Weekly symptom monitoring | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Weekly symptom monitoring
- description
- Web-based weekly symptom monitoring in addition to standard follow-up
- interventionNames
- Other: Weekly symptom monitoring
- type
- NO_INTERVENTION
- label
- Standard care
- description
- Standard follow-up according to guidelines
Primary outcomes (1)
- measure
- Overall survival
- timeFrame
- From date of randomization until the date of death from any cause, assessed up to 60 months.
- description
- Overall survival
Secondary outcomes (6)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically or cytology proven non-small cell lung cancer (NSCLC) * NSCLC stage III or IV * ≥ 18 years * ECOG performance status 0- 2 * Eligible patients should have initiated first-line treatment for advanced or metastatic disease with chemotherapy and/or immunotherapy, radiochemotherapy or targeted treatment * Patients are eligible for inclusion if they have responded to first-line treatment with stable disease, or better, at the first radiological evaluation performed up to six months after start of treatment * Stable disease, or better, on radiological assessment within 28 days of enrolment (CT scan or FDG-PET/CT. Cerebral MRI if known brain metastasis) * Initial web-based application score of ≤ 6 * Basic computer literacy * Bank-ID (electronic identification system) and access to "1177 Vårdguiden" * The subject has given written consent to participate in the study Exclusion Criteria: * Symptomatic brain metastases * Pregnancy, breastfeeding, or planned pregnancy * Persons under guardianship or deprived of liberty * Mental inability, reluctance or language difficulties that result in difficulty understanding the meaning of study participation * Treatment or disease which, according to the investigator, can affect treatment or study results * Ongoing participation in another interventional clinical study
References
Publications (5)
- BACKGROUNDDenis F, Basch E, Septans AL, Bennouna J, Urban T, Dueck AC, Letellier C. Two-Year Survival Comparing Web-Based Symptom Monitoring vs Routine Surveillance Following Treatment for Lung Cancer. JAMA. 2019 Jan 22;321(3):306-307. doi: 10.1001/jama.2018.18085. PMID 30667494
- BACKGROUNDTemel JS, Greer JA, El-Jawahri A, Pirl WF, Park ER, Jackson VA, Back AL, Kamdar M, Jacobsen J, Chittenden EH, Rinaldi SP, Gallagher ER, Eusebio JR, Li Z, Muzikansky A, Ryan DP. Effects of Early Integrated Palliative Care in Patients With Lung and GI Cancer: A Randomized Clinical Trial. J Clin Oncol. 2017 Mar 10;35(8):834-841. doi: 10.1200/JCO.2016.70.5046. Epub 2016 Dec 28. PMID 28029308
- BACKGROUNDNilsson J, Berglund A, Bergstrom S, Bergqvist M, Lambe M. The role of comorbidity in the management and prognosis in nonsmall cell lung cancer: a population-based study. Acta Oncol. 2017 Jul;56(7):949-956. doi: 10.1080/0284186X.2017.1324213. Epub 2017 May 9. PMID 28486004
- BACKGROUNDNipp R, Temel J. The Patient Knows Best: Incorporating Patient-Reported Outcomes Into Routine Clinical Care. J Natl Cancer Inst. 2017 Sep 1;109(9). doi: 10.1093/jnci/djx044. No abstract available. PMID 28423408
- BACKGROUNDBasch E, Snyder C. Overcoming barriers to integrating patient-reported outcomes in clinical practice and electronic health records. Ann Oncol. 2017 Oct 1;28(10):2332-2333. doi: 10.1093/annonc/mdx506. No abstract available. PMID 28961852